Synthetic Data for Healthcare AI

Industry Application

Synthetic DataHealthcare

Healthcare has arguably the most compelling use case for synthetic data of any industry. The sector sits at the intersection of two powerful forces: an insatiable demand for training data to power diagnostic AI, drug discovery, and clinical decision support—and some of the strictest privacy regulations on the planet. HIPAA in the United States, GDPR in Europe, and emerging frameworks worldwide make sharing real patient data across institutions, vendors, and research teams extraordinarily difficult. Synthetic data resolves this tension by generating artificial patient records, medical images, and clinical datasets that preserve the statistical properties of real populations without exposing any individual's protected health information.

The Privacy Imperative Driving Adoption

Healthcare organizations have long struggled with a fundamental paradox: the AI models that could most improve patient outcomes require exactly the kind of sensitive data that regulators exist to protect. Traditional de-identification approaches—stripping names, dates, and identifiers from records—have proven insufficient. Research consistently demonstrates that supposedly anonymized health records can be re-identified by cross-referencing with public datasets. Synthetic data offers a fundamentally different approach. Rather than attempting to obscure real records, platforms like MDClone and Syntegra generate entirely new patient populations that match the statistical distributions of real cohorts—disease prevalence, demographic breakdowns, comorbidity patterns, treatment trajectories—without any one-to-one correspondence to an actual patient.

The regulatory landscape is catching up. The U.S. Office for Civil Rights (OCR) prepared comprehensive AI-specific HIPAA guidance for release in early 2026, including requirements for synthetic data generation and differential privacy implementation. Fully synthetic datasets that contain zero real patient information may fall outside the definition of Protected Health Information entirely, though partially synthetic datasets blending real and artificial elements still require standard safeguards. Healthcare systems are increasingly treating synthetic data not as a workaround but as core privacy infrastructure.

Medical Imaging: Where Synthetic Data Has Crossed the Quality Threshold

Perhaps the most mature application of synthetic data in healthcare is medical imaging. Diffusion models and generative adversarial networks (GANs) now produce synthetic chest X-rays, CT scans, and MRI slices that are diagnostically indistinguishable from real images—even to experienced radiologists. Research published through the Radiological Society of North America (RSNA) in 2025 demonstrated that AI models trained on synthetic data performed comparably to those trained on real images, with performance improving significantly when synthetic images supplemented real datasets.

At the University of Colorado Anschutz Medical Campus, researchers developed a method published in Nature in mid-2025 that trains thyroid imaging classification models entirely on synthetic data. NVIDIA has expanded this frontier through its Clara platform, distilling from large language models based on chest X-ray reports to generate synthetic datasets of approximately 100,000 data points for training radiology AI. The implications are particularly significant for rare conditions—where real training examples may number in the dozens—and for reducing demographic bias in imaging AI by synthetically augmenting underrepresented populations.

Clinical Trials and Drug Discovery

Synthetic data is reshaping the economics and ethics of clinical research. Synthetic control arms—computationally generated comparison groups that mimic what would happen to patients receiving standard-of-care treatment—are already transforming evidence generation in oncology, hematology, and rare disease research, where small patient populations make traditional randomized recruitment nearly impossible.

The FDA has been running programs to understand the possibilities and limitations of supplementing patient datasets with synthetic data. While regulators are clear that synthetic data cannot replace real clinical evidence for safety and efficacy claims, they increasingly recognize its value for trial design optimization, site selection, patient recruitment planning, and identifying potential adverse event patterns before real-world data collection begins. SandboxAQ, leveraging NVIDIA's Structurally Augmented IC50 Repository (SAIR)—a synthetic collection of over five million 3D protein-ligand structures—has demonstrated that models trained on this data can predict binding affinities exponentially faster than traditional methods, accelerating early-stage drug discovery.

More than half of new clinical trials are projected to incorporate AI-driven protocol optimization using synthetic data by 2026, fundamentally changing how pharmaceutical companies plan and execute studies.

Rare Disease Research and Health Equity

Rare diseases—affecting fewer than 200,000 patients each in the U.S.—present an acute data scarcity problem. With patient populations sometimes numbering in the hundreds globally, there simply isn't enough real-world data to train reliable AI models. Synthetic data generation has emerged as a critical enabler, with research publications in this area growing from 24 in 2023 to 27 in 2025.

Deep generative models can simulate realistic genomic sequences across different demographics, effectively discovering drug targets and predicting the prevalence of rare genetic variants in larger synthetic populations. This capability is especially important for underrepresented populations in clinical research—synthetic data can create more inclusive trial designs by enriching populations that are historically excluded from studies. The UK's Medicines and Healthcare products Regulatory Agency (MHRA), through its Clinical Practice Research Datalink (CPRD), has been leading research on synthetic data for validation of AI algorithms and conditional boosting to address biases due to underrepresentation.

Market Trajectory

The healthcare segment is the fastest-growing vertical within the synthetic data market, projected to expand at a CAGR of 38.28% through 2033. The overall synthetic data generation market is expected to grow from $1.77 billion in 2026 to $7.22 billion by 2033. Healthcare's outsized share of this growth reflects the unique convergence of regulatory pressure, data sensitivity, and AI ambition that makes synthetic data not just useful but essential for the industry's digital transformation.

Applications & Use Cases

Synthetic EHR Generation

Platforms like MDClone and Syntegra generate complete synthetic electronic health records—longitudinal patient histories with diagnoses, medications, lab results, and clinical notes—that match real population distributions while containing zero protected health information. Health systems use these for cross-institutional research collaboration without data-sharing agreements.

Medical Imaging Augmentation

Diffusion models and GANs generate synthetic X-rays, CT scans, and MRIs to train diagnostic AI, particularly for rare conditions where real examples are scarce. NVIDIA Clara produces synthetic radiology datasets at scale, and CU Anschutz researchers have trained thyroid classification models entirely on synthetic images with results published in Nature.

Synthetic Control Arms for Clinical Trials

Computationally generated patient cohorts serve as comparison groups in rare disease and oncology trials, reducing the need for placebo arms in conditions where withholding treatment is ethically problematic. This accelerates trial timelines and reduces costs while maintaining regulatory rigor.

Drug Target Discovery

Synthetic molecular datasets like NVIDIA's SAIR—containing over five million 3D protein-ligand structures—enable AI models to predict binding affinities exponentially faster than wet-lab methods, compressing early-stage drug discovery timelines from years to months.

Bias Mitigation in Clinical AI

Synthetic data augments underrepresented demographic groups in training datasets, reducing the racial, gender, and age biases that plague clinical AI systems. RSNA research in 2025 confirmed that strategic synthetic augmentation measurably improves model fairness across patient populations.

Rare Disease Genomic Modeling

Generative models create synthetic genomic sequences that simulate variant distributions across diverse populations, enabling researchers to study conditions with as few as hundreds of known patients worldwide. This powers both diagnostic tool development and therapeutic target identification.

Key Players

MDClone — Healthcare-specific synthetic data platform founded in 2016, generates privacy-protected longitudinal patient data from heterogeneous health systems. Operates a multi-institutional health system research network and hosted the Synthetic Data Summit in 2025.
Syntegra — San Mateo-based synthetic healthcare data platform focused on improving patient care and clinical outcomes, generates synthetic patient populations for pharma and health system clients.
Gretel.ai — Developer-focused synthetic data platform with healthcare applications, provides fine-tuning for domain-specific generation with built-in privacy and quality metrics. Integrates into CI/CD pipelines for automated synthetic data workflows.
MOSTLY AI — Transforms production data into privacy-safe synthetic versions through a six-step process, with healthcare as a primary vertical. Includes AI Assistant for natural-language data exploration.
Syntho — AI-based engine specializing in privacy-sensitive sectors including healthcare, with features for time-series data, quality assurance reporting, and up-sampling for rare conditions.
NVIDIA — Clara platform generates synthetic medical imaging datasets at scale; SAIR repository provides over 5M synthetic 3D protein-ligand structures for drug discovery AI training.
SandboxAQ — Uses NVIDIA's synthetic molecular data to build AI models that predict drug-target binding affinities exponentially faster than traditional computational chemistry methods.
Hazy — Enterprise synthetic data platform with healthcare compliance focus, emphasizing data privacy and regulatory adherence for UK and EU health systems.

Challenges & Considerations

Fidelity vs. Privacy Tradeoffs — Higher-fidelity synthetic data more accurately reflects real patient populations but increases the risk of membership inference attacks—where adversaries determine if a specific patient's data was used to train the generator. Achieving k-anonymity while preserving clinically meaningful statistical relationships remains an active research challenge.
Regulatory Ambiguity — While the FDA and OCR are developing AI-specific guidance, the regulatory status of synthetic data varies by jurisdiction and use case. Fully synthetic datasets may not qualify as PHI under HIPAA, but partially synthetic blends occupy a gray area. EMA guidance expected in Q2 2026 may further complicate multinational research programs.
Distribution Shift and AI Rot — Models trained exclusively on synthetic data risk learning the biases and artifacts of the generator rather than real-world clinical patterns. The threat of "AI rot"—degradation from models training on synthetic-only loops—requires careful quality governance and validation against real-world outcomes.
Validation Burden — Proving that synthetic data faithfully represents the statistical properties of real patient populations requires access to... real patient populations. This creates a bootstrapping problem, particularly for institutions that turned to synthetic data precisely because they lack access to large real datasets.
Clinical Acceptance — Many clinicians and institutional review boards remain skeptical of research conducted on synthetic data. Building trust requires transparent methodology, reproducible benchmarks, and demonstrated equivalence with real-data studies—a cultural shift that lags behind the technical capability.
Cross-Institutional Heterogeneity — EHR data varies dramatically across health systems in coding practices, documentation standards, and data completeness. Synthetic data generators trained on one institution's data may produce outputs that don't generalize, limiting the utility of synthetic datasets for multi-site research without careful calibration.